180 related articles for article (PubMed ID: 31296342)
1. Update of therapeutic planning tables oriented towards obtaining therapeutic objectives.
Masana L; Plana N
Clin Investig Arterioscler; 2019; 31(6):271-277. PubMed ID: 31296342
[TBL] [Abstract][Full Text] [Related]
2. [Update of planning tables of cholesterol-lowering therapy orientated to achieve LDL therapeutic targets].
Masana L; Plana N
Clin Investig Arterioscler; 2015; 27(3):138-43. PubMed ID: 25865752
[TBL] [Abstract][Full Text] [Related]
3. Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?
Cervelli N; Tocci G; Ferri C
High Blood Press Cardiovasc Prev; 2018 Mar; 25(1):5-7. PubMed ID: 29305812
[No Abstract] [Full Text] [Related]
4. Practical guide for the use of PCSK9 inhibitors in Portugal.
Fontes-Carvalho R; Marques Silva P; Rodrigues E; Araújo F; Gavina C; Ferreira J; Morais J
Rev Port Cardiol (Engl Ed); 2019 Jun; 38(6):391-405. PubMed ID: 31324407
[TBL] [Abstract][Full Text] [Related]
5. Statins, Ezetimibe, and Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors to Reduce Low-Density Lipoprotein Cholesterol and Cardiovascular Events.
O'Keefe JH; DiNicolantonio JJ; Lavie CJ
Am J Cardiol; 2017 Feb; 119(4):565-571. PubMed ID: 28081940
[TBL] [Abstract][Full Text] [Related]
6. Lipid management in ACS: Should we go lower faster?
Gencer B; Mach F
Atherosclerosis; 2018 Aug; 275():368-375. PubMed ID: 30015301
[TBL] [Abstract][Full Text] [Related]
7. Determinants of Achieved LDL Cholesterol and "Non-HDL" Cholesterol in the Management of Dyslipidemias.
Packard CJ
Curr Cardiol Rep; 2018 Jun; 20(8):60. PubMed ID: 29904807
[TBL] [Abstract][Full Text] [Related]
8. LDL-cholesterol: The lower the better.
Pedro-Botet J; Pintó X
Clin Investig Arterioscler; 2019 Dec; 31 Suppl 2():16-27. PubMed ID: 31813618
[TBL] [Abstract][Full Text] [Related]
9. [A decade of progress in the management of dyslipidemia].
Wallemacq C; Paquot N
Rev Med Liege; 2020 May; 75(5-6):386-391. PubMed ID: 32496685
[TBL] [Abstract][Full Text] [Related]
10. LDL as a therapeutic objective.
Díaz Rodríguez Á; Mantilla Morató T
Clin Investig Arterioscler; 2019 Dec; 31 Suppl 2():1-15. PubMed ID: 31813617
[TBL] [Abstract][Full Text] [Related]
11. Drug insight: the role of statins in combination with ezetimibe to lower LDL cholesterol.
Gotto AM; Farmer JA
Nat Clin Pract Cardiovasc Med; 2006 Dec; 3(12):664-72. PubMed ID: 17122799
[TBL] [Abstract][Full Text] [Related]
12. PCSK9 inhibition for LDL lowering and beyond - implications for patients with peripheral artery disease.
Gebauer K; Reinecke H
Vasa; 2018 Apr; 47(3):165-176. PubMed ID: 29412075
[TBL] [Abstract][Full Text] [Related]
13. Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials.
Koskinas KC; Siontis GCM; Piccolo R; Mavridis D; Räber L; Mach F; Windecker S
Eur Heart J; 2018 Apr; 39(14):1172-1180. PubMed ID: 29069377
[TBL] [Abstract][Full Text] [Related]
14. A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.
Khan SU; Talluri S; Riaz H; Rahman H; Nasir F; Bin Riaz I; Sattur S; Ahmed H; Kaluski E; Krasuski R
Eur J Prev Cardiol; 2018 May; 25(8):844-853. PubMed ID: 29569492
[TBL] [Abstract][Full Text] [Related]
15. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.
Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ
JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335
[TBL] [Abstract][Full Text] [Related]
16. PCSK9 inhibitors: clinical evidence and implementation.
Sabatine MS
Nat Rev Cardiol; 2019 Mar; 16(3):155-165. PubMed ID: 30420622
[TBL] [Abstract][Full Text] [Related]
17. Combination Lipid-Lowering Therapies for the Prevention of Recurrent Cardiovascular Events.
Lee S; Cannon CP
Curr Cardiol Rep; 2018 May; 20(7):55. PubMed ID: 29802475
[TBL] [Abstract][Full Text] [Related]
18. A Clinical Guide to Combination Lipid-Lowering Therapy.
Russell C; Sheth S; Jacoby D
Curr Atheroscler Rep; 2018 Mar; 20(4):19. PubMed ID: 29516190
[TBL] [Abstract][Full Text] [Related]
19. Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry.
Virani SS; Kennedy KF; Akeroyd JM; Morris PB; Bittner VA; Masoudi FA; Stone NJ; Petersen LA; Ballantyne CM
Circ Cardiovasc Qual Outcomes; 2018 May; 11(5):e004652. PubMed ID: 29748356
[TBL] [Abstract][Full Text] [Related]
20. [Up to date lipid lowering treatment].
Paragh G; Karádi I
Orv Hetil; 2016 Jul; 157(31):1219-23. PubMed ID: 27476517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
